MA46337B1 - Pyridine compound - Google Patents
Pyridine compoundInfo
- Publication number
- MA46337B1 MA46337B1 MA46337A MA46337A MA46337B1 MA 46337 B1 MA46337 B1 MA 46337B1 MA 46337 A MA46337 A MA 46337A MA 46337 A MA46337 A MA 46337A MA 46337 B1 MA46337 B1 MA 46337B1
- Authority
- MA
- Morocco
- Prior art keywords
- pyridine compound
- pharmaceutically acceptable
- acceptable salt
- relates
- compound
- Prior art date
Links
- -1 Pyridine compound Chemical class 0.000 title 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
La présente invention concerne un composé ayant une action inhibitrice de la kinase ret ou un sel pharmaceutiquement acceptable de celui-ci, utile dans le traitement de maladies telles que le cancer. En particulier, l'invention concerne un composé représenté par la formule générale (i) suivante telle que définie dans la description : (i) ou un sel pharmaceutiquement acceptable de celui-ci.The present invention relates to a compound having an inhibitory action of ret kinase or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular, the invention relates to a compound represented by the following general formula (i) as defined in the description: (i) or a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016191725A JP2018052878A (en) | 2016-09-29 | 2016-09-29 | Pyridine compounds |
| PCT/GB2017/052913 WO2018060714A1 (en) | 2016-09-29 | 2017-09-28 | Pyridine compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA46337A MA46337A (en) | 2019-08-07 |
| MA46337B1 true MA46337B1 (en) | 2021-04-30 |
Family
ID=60020249
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA46337A MA46337B1 (en) | 2016-09-29 | 2017-09-28 | Pyridine compound |
| MA054910A MA54910A (en) | 2016-09-29 | 2017-09-28 | PYRIDINE SALTS AND METHOD |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054910A MA54910A (en) | 2016-09-29 | 2017-09-28 | PYRIDINE SALTS AND METHOD |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US10851092B2 (en) |
| EP (2) | EP3828178A1 (en) |
| JP (2) | JP2018052878A (en) |
| KR (1) | KR102520543B1 (en) |
| CN (2) | CN113788824A (en) |
| AU (2) | AU2017335242C1 (en) |
| BR (1) | BR112019006047A2 (en) |
| CA (1) | CA3035860A1 (en) |
| CL (1) | CL2019000844A1 (en) |
| CO (1) | CO2019004034A2 (en) |
| CY (1) | CY1123988T1 (en) |
| DK (1) | DK3519398T3 (en) |
| EA (1) | EA037103B1 (en) |
| EC (1) | ECSP19030134A (en) |
| ES (1) | ES2868748T3 (en) |
| HR (1) | HRP20210447T1 (en) |
| HU (1) | HUE054824T2 (en) |
| IL (1) | IL265630B (en) |
| LT (1) | LT3519398T (en) |
| MA (2) | MA46337B1 (en) |
| MD (1) | MD3519398T2 (en) |
| MX (1) | MX2019003747A (en) |
| PE (1) | PE20190805A1 (en) |
| PH (1) | PH12019500480A1 (en) |
| PL (1) | PL3519398T3 (en) |
| PT (1) | PT3519398T (en) |
| RS (1) | RS61640B1 (en) |
| SG (1) | SG11201901937WA (en) |
| SI (1) | SI3519398T1 (en) |
| SM (1) | SMT202100315T1 (en) |
| UA (1) | UA123964C2 (en) |
| WO (1) | WO2018060714A1 (en) |
| ZA (1) | ZA201902232B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3371171T3 (en) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitors of ret |
| JP2018052878A (en) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | Pyridine compounds |
| EP3740491A1 (en) | 2018-01-18 | 2020-11-25 | Array Biopharma, Inc. | Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors |
| CN111615514B (en) | 2018-01-18 | 2022-10-11 | 奥瑞生物药品公司 | Substituted pyrazolo [4,3-C ] pyridine compounds as RET kinase inhibitors |
| SI3773589T1 (en) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Ret inhibitor for use in treating cancer having a ret alteration |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| EP4062938A4 (en) * | 2019-11-18 | 2023-11-29 | Chugai Seiyaku Kabushiki Kaisha | Combination drug |
| CN113121524B (en) | 2019-12-31 | 2023-04-25 | 南京创济生物医药有限公司 | Heterocyclic sulfoxide imine compound, intermediate thereof, preparation method and application |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2021164741A1 (en) * | 2020-02-20 | 2021-08-26 | 南京明德新药研发有限公司 | Phenyl bisamide compound |
| CN115210226B (en) * | 2020-02-20 | 2024-01-09 | 广州白云山医药集团股份有限公司白云山制药总厂 | Quinoline compounds |
| JP2023527412A (en) | 2020-05-29 | 2023-06-28 | ブループリント メディシンズ コーポレイション | Solid form of pralcetinib |
| WO2022238706A1 (en) | 2021-05-14 | 2022-11-17 | Bp Asset Viii, Inc. | Ret inhibitor for the treatment of ret altered medullary thyroid cancer or ret altered non-small cell lung cancer |
| JP2024539137A (en) | 2021-10-22 | 2024-10-28 | ユニバーシティー オブ ヒューストン システム | Methods and compositions for treating chronic inflammatory injury, metaplasia, dysplasia, and cancer of epithelial tissues - Patents.com |
| CN115090331B (en) * | 2022-07-21 | 2023-05-16 | 扬州大学 | Supermolecule chiral catalyst, preparation method thereof and application of supermolecule chiral catalyst in catalyzing D-A reaction |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| JP2009528335A (en) | 2006-03-02 | 2009-08-06 | アストラゼネカ アクチボラグ | Quinazoline derivatives |
| US20090076075A1 (en) | 2006-03-02 | 2009-03-19 | Frederic Henri Jung | Quinoline derivatives |
| WO2007113548A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives |
| WO2007113565A1 (en) | 2006-04-06 | 2007-10-11 | Astrazeneca Ab | Naphthyridine derivatives as anti-cancer agents |
| FR2933700B1 (en) | 2008-07-08 | 2010-07-30 | Sanofi Aventis | PYRIDINO-PYRIDINONE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
| WO2010098428A1 (en) * | 2009-02-27 | 2010-09-02 | 帝人ファーマ株式会社 | Process for producing phenyl-substituted heterocyclic derivative through coupling using transition metal catalyst |
| JP2013502429A (en) | 2009-08-19 | 2013-01-24 | アムビト ビオスシエンセス コルポラチオン | Biaryl compounds and methods of use thereof |
| PL2470173T3 (en) | 2009-08-25 | 2016-11-30 | Combination therapy with nanoparticle compositions of taxane and hedgehog inhibitors | |
| EP2560652A4 (en) | 2010-04-23 | 2013-08-14 | Kineta Inc | ANTIVIRAL COMPOUNDS |
| US9073895B2 (en) | 2010-12-16 | 2015-07-07 | Boehringer Ingelheim International Gmbh | Biarylamide inhibitors of leukotriene production |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| BR112015023618A2 (en) | 2013-03-15 | 2017-07-18 | Glaxosmithkline Ip Dev Ltd | pyridine derivatives as reorganized kinase inhibitors during transfection (ret) |
| KR20160055170A (en) * | 2013-08-30 | 2016-05-17 | 암비트 바이오사이언시즈 코포레이션 | Biaryl acetamide compounds and methods of use thereof |
| GB201321146D0 (en) | 2013-11-29 | 2014-01-15 | Cancer Rec Tech Ltd | Quinazoline compounds |
| US9783522B2 (en) * | 2014-04-24 | 2017-10-10 | Mitsubishi Tanabe Pharma Corporation | 2-amino-pyridine and 2-amino-pyrimidine derivatives and medicinal use thereof |
| EA032030B1 (en) * | 2014-09-10 | 2019-03-29 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Compounds as rearranged during transfection (ret) kinase inhibitors |
| PE20170705A1 (en) * | 2014-09-10 | 2017-05-21 | Glaxosmithkline Ip Dev Ltd | NEW COMPOUNDS AS RET INHIBITORS (REORGANIZED DURING TRANSFECTION) |
| CN107427506A (en) | 2014-10-14 | 2017-12-01 | 拉霍拉敏感及免疫学研究所 | Inhibitors of low molecular weight protein tyrosine phosphatases and uses thereof |
| CN104844589B (en) | 2014-12-26 | 2018-04-20 | 中国科学院合肥物质科学研究院 | A kind of PI3K kinase inhibitors |
| US10202365B2 (en) * | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| BR112018000808A2 (en) | 2015-07-16 | 2018-09-04 | Array Biopharma Inc | substituted pyrazolo [1,5-a] pyridine compounds as retinase inhibitors |
| JP2018052878A (en) * | 2016-09-29 | 2018-04-05 | 第一三共株式会社 | Pyridine compounds |
-
2016
- 2016-09-29 JP JP2016191725A patent/JP2018052878A/en active Pending
-
2017
- 2017-09-28 SM SM20210315T patent/SMT202100315T1/en unknown
- 2017-09-28 CN CN202111188408.2A patent/CN113788824A/en active Pending
- 2017-09-28 CN CN201780074582.XA patent/CN110036007B/en active Active
- 2017-09-28 UA UAA201904549A patent/UA123964C2/en unknown
- 2017-09-28 PT PT177801693T patent/PT3519398T/en unknown
- 2017-09-28 BR BR112019006047A patent/BR112019006047A2/en not_active Application Discontinuation
- 2017-09-28 CA CA3035860A patent/CA3035860A1/en active Pending
- 2017-09-28 PE PE2019000730A patent/PE20190805A1/en unknown
- 2017-09-28 AU AU2017335242A patent/AU2017335242C1/en not_active Ceased
- 2017-09-28 SG SG11201901937WA patent/SG11201901937WA/en unknown
- 2017-09-28 US US16/337,896 patent/US10851092B2/en active Active
- 2017-09-28 SI SI201730683T patent/SI3519398T1/en unknown
- 2017-09-28 MA MA46337A patent/MA46337B1/en unknown
- 2017-09-28 MA MA054910A patent/MA54910A/en unknown
- 2017-09-28 DK DK17780169.3T patent/DK3519398T3/en active
- 2017-09-28 KR KR1020197012323A patent/KR102520543B1/en active Active
- 2017-09-28 ES ES17780169T patent/ES2868748T3/en active Active
- 2017-09-28 EP EP21151210.8A patent/EP3828178A1/en not_active Withdrawn
- 2017-09-28 LT LTEP17780169.3T patent/LT3519398T/en unknown
- 2017-09-28 WO PCT/GB2017/052913 patent/WO2018060714A1/en not_active Ceased
- 2017-09-28 HR HRP20210447TT patent/HRP20210447T1/en unknown
- 2017-09-28 EA EA201990833A patent/EA037103B1/en unknown
- 2017-09-28 RS RS20210332A patent/RS61640B1/en unknown
- 2017-09-28 MD MDE20190863T patent/MD3519398T2/en unknown
- 2017-09-28 EP EP17780169.3A patent/EP3519398B1/en active Active
- 2017-09-28 MX MX2019003747A patent/MX2019003747A/en unknown
- 2017-09-28 HU HUE17780169A patent/HUE054824T2/en unknown
- 2017-09-28 JP JP2019516670A patent/JP7098609B2/en not_active Expired - Fee Related
- 2017-09-28 PL PL17780169T patent/PL3519398T3/en unknown
-
2019
- 2019-03-05 PH PH12019500480A patent/PH12019500480A1/en unknown
- 2019-03-26 IL IL265630A patent/IL265630B/en unknown
- 2019-03-28 CL CL2019000844A patent/CL2019000844A1/en unknown
- 2019-04-09 ZA ZA2019/02232A patent/ZA201902232B/en unknown
- 2019-04-23 CO CONC2019/0004034A patent/CO2019004034A2/en unknown
- 2019-04-29 EC ECSENADI201930134A patent/ECSP19030134A/en unknown
-
2020
- 2020-11-24 US US17/103,515 patent/US20210163464A1/en not_active Abandoned
-
2021
- 2021-03-17 CY CY20211100228T patent/CY1123988T1/en unknown
- 2021-11-03 AU AU2021261899A patent/AU2021261899A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA46337A (en) | PYRIDINE COMPOUND | |
| SA518400547B1 (en) | Pyrazolopyrimidine Derivatives as Kinase Inhibitor | |
| MA52948B1 (en) | COMPOUNDS | |
| MA38390B1 (en) | Tetrahydropyrrolothiazine compounds | |
| MX2022006783A (en) | NEW METHYLQUINAZOLINONE DERIVATIVES. | |
| EA201890473A1 (en) | Heteroaryl Derivatives as PARP Inhibitors | |
| MA35861B1 (en) | Kinase inhibitor regulating the signals of apoptosis | |
| EA202092253A1 (en) | SUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS PRMT5 INHIBITORS | |
| MA38454A1 (en) | Protein kinase inhibitors | |
| CL2017003032A1 (en) | Pyrido [3,4-d] pyrimidine derivative and pharmaceutically acceptable salt thereof | |
| MX391812B (en) | STEROID-DERIVED FXR AGONIST. | |
| EA202193015A1 (en) | CDK INHIBITORS | |
| BR112017019286A2 (en) | As anti-cancer drugs substituted 2-hydroperoxy-pyrazole derivative | |
| MX375323B (en) | MITOGEN-ACTIVATED PROTEIN KINASE (MNK) INTERACTING KINASE INHIBITORS AND METHODS RELATED THERETO. | |
| MY194468A (en) | Oxy-fluoropiperidine derivatives as kinase inhhiitor | |
| MX373786B (en) | PYRIMIDIN-2,4-DIAMINE DERIVATIVES FOR THE TREATMENT OF CANCER. | |
| MD4659B1 (en) | Polymorph of SYK inhibitors | |
| JOP20200086B1 (en) | Condensed imidazole derivatives with tertiary hydroxylated substitutions act as PI3K-gamma inhibitors. | |
| MA39983B1 (en) | Carboxamide derivatives | |
| MA39152B1 (en) | 1,2-substituted cyclopentanes used as orexin receptor antagonists | |
| SA523451905B1 (en) | Substituted Pyrimidinyl-Pyrazoles as CDK2 Inhibitors | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| EA201692557A1 (en) | CINOLYSINUM DERIVATIVES AS PI3K INHIBITORS | |
| MX2020013297A (en) | Compound for treatment or prevention of liver diseases. | |
| MX2021007258A (en) | Amorphous sparsentan compositions. |